Feb 8th 2023 - Mar 22nd 2023
Sales improving, patent safe, patent extension 203... See more
That together with no competition in the field, pa... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 8th 2023 - Mar 22nd 2023
$RSLS patent, approved, patent approved, patent ap... See more
$RSLS it’s a great squeeze scenario, fill the $12 ... See more
No reviews available.
Sales improving, patent safe, patent extension 2037, increase in insurance covering.
That together with no competition in the field, patent life, IPR out of the way is a mix of cocktails that favors BO.
Blockbuster drug with improving sales and long patent life
$AUPH patent is safe.
It was easy when you had that patent lock on you.
The patent challenges are now over and IP protection is very solid.
$AUPH The BBT TRX/NRX numbers are showing a significant jump, the patent challenges are over and new patents solidify the IP, the revenue outlook Peter provided is obviously very easy to beat, especially if TRX/NRX numbers continue high.
Anyway, the Patent’s they filed for again Europe and US, what’s the guess for approval and think that would be a big plus on BO.
$RSLS patent, approved, patent approved, patent approved…it’s going up up and away
$RSLS it’s a great squeeze scenario, fill the $12 daily gap, and don’t forget the patent
$RSLS great patent and more news coming
$RSLS nice formation, great, volume, strong rsi, and let’s not forget patent was approved
$RSLS The good old patent pump! 😂
